Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 04:31 pm EDT
Share
Xenetic Biosciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.651005 million compared to USD 0.41671 million a year ago. Net loss was USD 1.05 million compared to USD 2.67 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 1.9 a year ago. Diluted loss per share from continuing operations was USD 0.69 compared to USD 1.9 a year ago.
For the six months, revenue was USD 1.26 million compared to USD 0.805703 million a year ago. Net loss was USD 1.91 million compared to USD 4.27 million a year ago. Basic loss per share from continuing operations was USD 1.25 compared to USD 3.1 a year ago. Diluted loss per share from continuing operations was USD 1.25 compared to USD 3.1 a year ago.
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
XENETIC BIOSCIENCES, INC. 
